At the IGTP TODAY

News

- Campus Can Ruti, Research

New financing from the Catalan NF2 Patients Association for Research into personalized medicine for Neurofibromatosis Type 2

Can Ruti has been awarded a research project by the Spanish Federation for Rare Diseases (FEDER) Foundation in their fourth call for research projects.  The winning project, led by Dr Ignacio Blanco and Dr Elisabeth Castellanos, from the Germans Trias I Pujol Hospital and Institute respectively, is one of five financed by the foundation this year. The research will focus personalized attention for Neurofibromatosis type 2 (NF2) patients to optimize evaluation of their quality of life and refine their classification during diagnosis.

- Research

Elisa Martró awarded a project for Micro-elimination of Hepatitis C by GILEAD

Elisa Martró, leader of the Clinical Virology and New Diagnostic Approaches Research Group at the Microbiology Service of the Germans Trias i Pujol Hospital, has been awarded with one of the five projects granted in the First Edition of the Gilead projects for Micro-elimination of Hepatitis C in Spain and evaluated by the Spanish Liver Research Association (AEEH).

- Research

Can Ruti shows it cares for rare diseases

The IGTP and the Germans Trias Hospital face the spotlight for rare diseases again.  This year our professionals are joining World Rare Disease Day on the last day of February to highlight these diseases and shine a light on the research activities in the field on campus.

- Research

An update on advances in stroke therapy

The Cellular and Molecular Neurobiology Research Group, led by Teresa Gasull at the IGTP has a mission to carry out basic and translational research into strokes.  This week they have published a review of recent advances in the field, which includes the role of the ferroptosis in stroke-induced neurodegeneration and includes references to their own recent publications in the field.

- Research

The Digestive Inflammatory Pathology Research Group awarded the prize for best research project at the Catalan Digestive Medicine Conference

A study by the Digestive Inflammatory Pathology Research Group at the IGTP was awarded the best basic-translational research study in the Catalan Digestive Medicine Conference 2019.  The study presented by Dr Violeta Lorén is within one of the main research lines of the group and centres on understanding, predicting and solving one of the main complications arising from therapy for patients with ulcerative colitis: the failure of glucocorticoid treatment.

- Research

Induced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer

The study, by the Hereditary Cancer research group at the IGTP, focuses on characterizing induced pluripotent stem cells (iPSCs) from benign tumors, characteristic of Neurofibromatosis type 1 (NF1). The iPSCs are able to regenerate indefinitely and give rise to any other cell in the body so they represent an inexhaustible supply of cells to study tumors and new treatments.

Participants in the GCAT Project take a look behind the scenes

How do they do it?  How do they get genetic information from a blood sample?  How do you manage the genetic information of 20,000 people? How do you get to understand all this information so it can be used for research?  These are some of the questions asked by GCAT participants while visiting the National Centre for Genomics Analysis- Centre for Genomic Regulation (CNAG-CRG) and Barcelona Supercomputing Centre (BSC), both centres are collaborating with the project.  These questions now have answers.

- Research

New indications of prenatal environmental factors affecting risk of developing type 1 diabetes

A new study by the Immunology of Diabetes Group, led by Marta Vives-Pi at the IGTP in conjunction with the University Medical Centre Hamburg-Eppendorf, builds on previous work led by the group in Hamburg.  The new study looks into the effect of betamethasone on new-borns and its susceptibility to develop type 1 diabetes, when it is administered to mothers before birth. As well as corroborating the previous results and finding new changes in the developing immune system, the results also throw light onto the effect of the drug on the insulin-producing cells themselves.

- Research

A study optimizes the probability of success for allogenic cell therapy in patients with heart failure

Researchers from the Heart Disease Research Group at the IGTP and the CIBER Cardiovascular Group both led by Dr Antoni Bayés prepare the way to optimize reparative cell therapy in heart failure patients. The study, carried out in conjunction with the Immunogenetics and Histocompatibility Laboratory and the Cell Therapy Unit of the Blood and Tissue Bank of Barcelona has studied the HLA allele and the frequency of haplotypes in a cohort of patients with heart failure as the first stage in optimizing future allogenic cell therapies for these patients.